Table 5 Ocular gene transfer risks and challenges in Canadian, United Kingdom, and United States newspapers
From: Ocular gene transfer in the spotlight: implications of newspaper content for clinical communications
Gene transfer risks, challenges, or caveats | Percent (%) of articles | P-valuea | ||
|---|---|---|---|---|
|  | Canada (n = 26) | United Kingdom (n = 77) | United States (n = 55) |  |
Not mentioned | 35 | 69 | 53 | 0.006* |
General health risk | 19 | 17 | 33 | 0.098 |
Efficacy concerns | 35 | 9 | 18 | 0.003* |
New research or first-in-human experimentation | 12 | 8 | 5 | 0.607 |
Long timeline to clinical implementation | 15 | 5 | 4 | 0.002* |
Historical adverse events in gene transfer clinical trials | 8 | 0 | 11 | 0.006* |
Eye health risk | 8 | 3 | 7 | 0.299 |
Unknown risk/Uncertain risk | 15 | 0 | 5 | 0.003* |
Complexity of gene transfer | 4 | 6 | 0 | 0.143 |
Economic risk | 11 | 0 | 0 | 0.004* |
Ethical challenges | 4 | 0 | 0 | 0.075 |
Social challenges | 0 | 1 | 0 | 1.000 |
Quality of life concerns arising from clinical trial participation | 4 | 0 | 0 | 0.165 |
Legal risk | 0 | 0 | 0 | 1.000 |